Product Description
Mechanisms of Action: Osteoclast Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Algeria | Australia | Austria | Belgium | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Czech | Dominican Republic | Egypt | Finland | France | Germany | Greece | Hong Kong | Hungary | Indonesia | Ireland | Israel | Italy | Jordan | Malta | Mexico | Morocco | Netherlands | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Slovenia | Spain | Sweden | Taiwan | Thailand | Tunisia | Turkey | United Kingdom | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Elanco Animal Health
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Italy
Active Clinical Trial Count: 3
Highest Development Phases
Phase 3: Osteoarthritis, Knee
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
SPA-S-899-01-21 | P3 |
Not yet recruiting |
Osteoarthritis, Knee |
2025-10-01 |
|
SPA-S-899-01-21 | P3 |
Recruiting |
Osteoarthritis, Knee |
2025-07-01 |
|
SPA-S-899-01-21 | P3 |
Active, not recruiting |
Osteoarthritis, Knee |
2025-05-15 |